Mar 10, 2025
For nearly three decades, Genentech has been the sole provider of an approved medication for acute stroke treatment. On 03 March 2025, the Roche subsidiary expanded its stroke treatment portfolio with FDA approval for TNKase (tenecteplase). TNKase (tenecteplase) is a thrombolytic, clot-dissolving tis...
Read More...
Mar 06, 2023
Acute ischemic stroke, contributing up to 80% of all stroke cases, is among the leading causes of death and morbidity, leaving around 50% of stroke survivors disabled worldwide. It is caused due to the blockage of an artery resulting in reduced blood flow to the brain that damages and interrupts brain functions. Hi...
Read More...
LEQEMBI: A New Hope for Alzheimer’s Disease Patients
Feb 12, 2025
Roche’s HER2-Positive Breast Cancer Treatment Franchise
Aug 13, 2024
Newsletter/Whitepaper